低剖面与标准剖面开窗分支支架移植物治疗复杂腹主动脉及胸腹主动脉瘤的结局
该前瞻性非随机研究纳入2013至2021年466例接受开窗分支腔内修复术的复杂腹主动脉瘤及胸腹主动脉瘤患者,比较低剖面(18F-20F)与标准剖面(20F-22F)支架的结局。两组技术成功率和30天主要不良事件无差异,低剖面组手术时间更短、辐射和造影剂更少,但支架完整性相关问题更多,瘤囊缩小率更高。
要点
- 低剖面组与标准剖面组技术成功率分别为96%与97%,30天主要不良事件无差异。
- 低剖面组总手术时间更短、辐射剂量和造影剂用量更少,髂动脉 conduit 使用更少。
- 低剖面组4年免于任何完整性相关问题的比例更低(92%±5% vs 100%,P<.001)。
核心结论
- 低剖面与标准剖面支架行开窗分支腔内修复术的死亡率和主要不良事件发生率均低,但低剖面组瘤囊缩小累积风险更高(校正HR 2.040,95%CI 1.516-2.744,P<.001),支架完整性结果需未来研究。
研究设计与样本
- 前瞻性非随机研究,纳入2013至2021年466例连续患者(70%男性,平均年龄74±8岁),比较低剖面(18F-20F)与标准剖面(20F-22F)开窗分支腔内修复术的结局。
主要发现
- 低剖面组与标准剖面组技术成功率分别为96%与97%(P=.527),髂股入路并发症分别为1.3%与3.5%(P=.107),30天主要不良事件两组无差异。
- 低剖面组总手术时间225±81分钟 vs 标准剖面组243±78分钟(P=.018),辐射剂量中位数0.93 Gy(IQR 0.94)vs 1.01 Gy(IQR 0.91 Gy)(P<.001),造影剂中位数135 mL(IQR 68 mL)vs 144 mL(IQR 80 mL)(P=.008)。
- 平均随访28个月(95%CI 25-30个月),4年低剖面组与标准剖面组全因死亡免除率分别为69%±6%与68%±4%(P=.199),主动脉相关死亡免除率分别为97%±1%与98%±1%(P=.488),任何二次干预免除率分别为65%±6%与70%±4%(P=.433),血栓栓塞事件免除率分别为98%±1%与99%±1%(P=.364),瘤囊增大免除率分别为93%±3%与91%±3%(P=.293)。
- 低剖面组免于任何完整性相关问题的比例低于标准剖面组(92%±5% vs 100%,P<.001)。
- 低剖面组瘤囊缩小的累积风险高于标准剖面组(校正HR 2.040,95%CI 1.516-2.744,P<.001)。
临床怎么用
- 作者认为低剖面支架行开窗分支腔内修复术的死亡率和主要不良事件发生率低,且低剖面组髂动脉 conduit 使用更少、手术指标更好、瘤囊缩小率更高。
- 作者指出支架完整性结果需未来研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We compared the outcomes of fenestrated-branched (FB) endovascular abdominal aortic aneurysm repair (EVAR) using low-profile (LP) and standard-profile (SP) stent grafts for the treatment of complex abdominal aortic aneurysms (CAAAs) and thoracoabdominal aortic aneurysms (TAAAs). METHODS: We reviewed the clinical data of 466 consecutive patients (70% male; mean age, 74 ± 8 years) enrolled in a prospective nonrandomized study to investigate FB-EVAR for the treatment of CAAAs and TAAAs (2013-2021). The endpoints compared between the patients treated with LP (18F-20F) and SP (20F-22F) devices included procedural metrics, access-related complications, major adverse events (MAE), patient survival, freedom from secondary intervention, thromboembolic events, stent graft integrity issues, aneurysm sac enlargement, and the rate of sac shrinkage. RESULTS: Of the 466 aneurysms treated by FB-EVAR, 138 were CAAAs and 141 were extent IV and 187 extent I to III TAAAs, with a mean number of 3.9 ± 0.5 vessels stented per patient. LP devices had been used in 239 patients (51%) and SP devices in 227 patients (49%). LP devices had been used more frequently for chronic dissections (12% vs 7%; P = .041) and with preloaded systems (77% vs 65%; P = .005) and bilateral percutaneous femoral access (83% vs 74%; P = .020) and less frequently with upper extremity access (67% vs 88%; P < .001) and iliac conduits (2% vs 6%; P = .020). The patients treated using LP devices had experienced similar technical success (96% vs 97%; P = .527), with a shorter total operating time (225 ± 81 minutes vs 243 ± 78 minutes; P = .018), lower radiation exposure (median, 0.93 Gy; interquartile range [IQR], 0.94; vs median, 1.01 Gy; IQR, 0.91 Gy; P < .001), and less use of contrast (median, 135 mL; IQR, 68 mL; vs median, 144 mL; IQR, 80 mL; P = .008). No differences were found in the rates of iliofemoral access complications between the LP and SP device groups (1.3% vs 3.5%; P = .107). At 30 days, 5 patients had died (1%) and MAEs had occurred in 89 patients (19%), with no differences between the two groups. The mean follow-up was 28 months (95% confidence interval, 25-30 months). At 4 years, the patients treated with LP devices had had similar freedom from all-cause mortality (69% ± 6% vs 68% ± 4%; P = .199), freedom from aortic-related mortality (97% ± 1% vs 98% ± 1%; P = .488), freedom from any secondary intervention (65% ± 6% vs 70% ± 4%; P = .433), freedom from thromboembolic events (98% ± 1% vs 99% ± 1%; P = .364) and aneurysm sac enlargement (93% ± 3% vs 91% ± 3%; P = .293). However, the LP group had had less freedom from any integrity-related issues (92% ± 5% vs 100%; P < .001). The cumulative risk of sac shrinkage was greater for patients treated with LP devices (adjusted hazard ratio, 2.040; 95% confidence interval, 1.516-2.744; P < .001). CONCLUSIONS: FB-EVAR was performed with low rates of mortality and MAEs, irrespective of the device profile. However, the procedures performed with LP devices had had less need for iliac conduits and had had better procedural metrics. The use of LP devices resulted in higher rates of sac shrinkage. However, the results on stent graft integrity require future investigation.
引用
- Dias-Neto M, Tenorio ER, Lima GBB, et al. Outcomes of low- and standard-profile fenestrated and branched stent grafts for treatment of complex abdominal and thoracoabdominal aortic aneurysms. J Vasc Surg. 2022. PMID: 35810953. doi:10.1016/j.jvs.2022.05.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。